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Abstract. In this study, we sought to determine the predic-
tors of pathological complete response (pCR) and compare 
the chemotherapeutic regimens administered to breast cancer 
patients with and those without pCR. We retrospectively 
reviewed the data of 879 patients treated at the Alvin J. Siteman 
Cancer Center between 2006 and 2010, to identify patients 
who were diagnosed with primary stage II or III breast cancer 
and received neoadjuvant chemotherapy. Patients who received 
only neoadjuvant endocrine therapy were considered to be inel-
igible. Patient, tumor, and treatment characteristics, including 
type of chemotherapy, were compared between patients who 
did and those who did not achieve pCR using Chi-square or 
Fisher's exact tests and multivariate logistic regression analysis. 
Two‑sided P‑values of <0.05 were considered significant. Of 
the 333 patients who met the inclusion criteria, 61 (18.3%) had 
documented pCR. Compared with patients not achieving pCR, 
a greater proportion of patients with pCR had stage II disease 
(80.3 vs. 68%, P=0.057), had poorly differentiated (grade 3) 
tumors (82 vs. 59.2%, P<0.001), had negative lymph node 
involvement (41 vs. 34%, P=0.0004) and had tumors that were 
HER2‑amplified (41 vs. 23.5%, P=0.0054). A greater propor-
tion of patients with pCR received taxane-based chemotherapy 
(23 vs. 12.5%, P=0.016) or trastuzumab in conjunction with 
chemotherapy (41.0 vs. 16.9%, P<0.001). No patients receiving 
solely anthracycline-based therapy achieved pCR in our study. 
Our study demonstrated that, for stage II and III breast cancer, 
lower stage, negative lymph node involvement and HER2 
receptor amplification were each associated with pCR. Taxane 
therapy and the concurrent use of trastuzumab were also asso-
ciated with a higher likelihood of pCR.
Introduction
Neoadjuvant chemotherapy for the treatment of breast cancer 
has undergone significant evolution over time. Historically, 
neoadjuvant chemotherapy was used only for tumors consid-
ered inoperable at presentation. However, this changed after 
the publication of the well-known National Surgical Adjuvant 
Breast and Bowel Project study results, which demonstrated 
that neoadjuvant chemotherapy, in comparison to adjuvant, 
was not associated with significant differences in disease‑free 
or overall survival and was associated with higher rates of 
breast-conserving surgery (1,2). Neoadjuvant chemotherapy 
use was subsequently broadened to include large, operable 
tumors with the aim of achieving breast conservation.
In addition to breast conservation, neoadjuvant chemo-
therapy allows for an in vivo assessment of response to therapy, 
while also providing early treatment of the primary tumor and 
potential micrometastatic disease (3). Pathological complete 
response (pCR), often used as a surrogate endpoint to assess 
the efficacy of neoadjuvant chemotherapy, is also considered to 
be a strong prognostic measure of long-term clinical outcomes, 
including disease-free and overall survival (4-6). Hence, iden-
tifying and validating factors which predict pCR or improve 
pCR rates are crucial in breast cancer management.
Furthermore, anthracyclines have been considered tradi-
tionally as the most standard and active among breast cancer 
chemotherapy drugs. In an effort to improve pCR rates, other 
studies investigated the impact of combining different chemo-
therapeutic agents in the neoadjuvant setting (7-10). In our study, 
we not only sought to identify pCR rates and predictors at a 
single institution, but also to examine the administered chemo-
therapeutic regimens, and compare and contrast the regimens 
between patients who did and those who did not achieve pCR.
Patients and methods
Patient selection. During a retrospective review of 879 patients 
who were treated for a first primary breast cancer at the 
Alvin J. Siteman Cancer Center between January, 2006 and 
December, 2010, we identified patients who received neoad-
juvant chemotherapy for pathologically confirmed invasive 
(stage II and III) breast cancer. We restricted our analysis to 
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stage II and III disease in the specified 5‑year period in order to 
evaluate a more homogeneous population of patients receiving 
neoadjuvant chemotherapy, with or without other neoadjuvant 
treatment, as neoadjuvant treatment decisions were likely 
made based on similar overarching guidelines during this 
period (based on tumor size and grade, presence or absence 
of lymph node metastases, receptor status and recommended 
chemotherapeutic regimens). The medical records of patients 
who received neoadjuvant chemotherapy were reviewed, to 
determine which of these patients' tumors exhibited a pCR, 
defined as no evidence of residual invasive malignancy in the 
breast or axilla. As ductal carcinoma in situ (DCIS) generally 
does not regress with chemotherapy and evidence of its impact 
on prognosis is equivocal (11,12), patients with only residual 
DCIS following neoadjuvant systemic therapy were included 
in the pCR cohort. Patients who received only neoadjuvant 
endocrine therapy without mention of chemotherapy in the 
neoadjuvant setting were deemed ineligible for inclusion, 
mainly to avoid including patients who rarely achieve pCR, as 
previous studies have demonstrated that, while a large number 
of patients undergoing neoadjuvant endocrine therapy display 
some evidence of clinical response, pCR is infrequent (13-16). 
Additionally, we determined the specific neoadjuvant systemic 
therapy received by each of the identified patients to assess 
the potential impact of the chemotherapeutic regimen received 
on the pCR rates observed. The regimen administered to each 
patient was selected at the discretion of the medical oncologist, 
based on established standards or clinical trials in place at the 
time of therapy.
This study was initiated after Institutional Review Board 
approval was obtained, with a waiver of consent given the 
retrospective nature of the study.
Statistical analysis. We used the Wilcoxon rank-sum tests 
(for continuous variables), Chi-square or Fisher's exact tests 
(for categorical variables) and unadjusted logistic regression 
to examine clinical characteristics potentially associated with 
pCR, including age, race, lymph node involvement, histology, 
TNM stage, tumor grade, estrogen receptor (ER) and proges-
terone receptor (PR) status, and presence of HER2 amplification. 
Tumor size was not examined as a discrete variable, but rather 
as a component of stage. Biomarker/receptor status, stage and 
factors significant at P<0.2 in unadjusted tests were included 
as independent variables in multivariate logistic regression 
models that were further refined using backwards elimination.
Two regression models for the outcome pCR as a 
yes/no binary measure were created, one featuring each 
individual receptor status (i.e., PR, HER2) and the other 
using a composite biomarker status reported of hormone 
receptor status plus/minus HER2 amplification. A hormone 
receptor‑positive (HR+) cancer was defined as an ER‑positive 
and/or PR-positive cancer, whereas a hormone receptor-nega-
tive (HR-) cancer was defined as an ER-negative and/or 
PR‑negative cancer. These definitions led to the generation 
of four categories for comparison in the composite biomarker 
analysis as follows: HR+/HER2-, HR+/HER2+, HR-/HER2- 
and HR-/HER2+. Additionally, grade was analyzed by 
combining well- and moderately differentiated cancers 
(grade 1 and 2) and comparing them to poorly differenti-
ated cancers (grade 3). We report adjusted odds ratios (ORs) 
and 95% confidence intervals (CIs) significant at two-tailed 
P<0.05. The statistical analyses were conducted using SAS 9.3 
software (SAS Institute Inc., Cary, NC, USA).
Results
pCR rates and predictors. Over the 5-year period reviewed, 
333 patients received neoadjuvant chemotherapy. Among these 
patients, the majority had stage II disease (70.3%) and tumors 
that were ER+ (52.3%), PR- (55.9%), HER2-non-amplified 
(HER2-; 73.3%), poorly differentiated (i.e., grade 3; 63.4%), 
and a ductal histology (77.5%). A total of 61 patients (18.3%) 
had pCR. Descriptive statistics of the study sample grouped by 
pCR status are shown in Table I.
In unadjusted tests, pCR was associated with higher tumor 
grade (P=0.0035), no lymph node involvement (P=0.0013), 
HER2 amplification (P=0.0061), ER‑negative (P=0.027) and 
PR-negative status (P<0.001). Also observed was an inverse 
association between pCR and HR+/HER2- status (P<0.001). 
These results are shown in Table II.
The results of separate multivariate logistic regression 
models, one featuring individual biomarkers and the other 
including composite biomarkers, are also reported in Table II. 
In the model featuring individual biomarkers, HER2 amplifica-
tion (P=0.0095), PR-negative status (P=0.0081) and absence of 
lymph node involvement (P=0.0039) predicted a higher likeli-
hood of pCR. In the multivariate model including the composite 
biomarkers, the HR+/HER2- subtype and any lymph node 
involvement (P=0.0049) resulted in a lower likelihood of pCR.
Neoadjuvant systemic therapy. Of the 333 patients in the study 
sample, complete records of the administered chemothera-
peutic regimens were available for 323 (97%); 252 patients 
received a combined regimen of anthracyclines and taxanes, 
48 received a taxane-only regimen, 19 received an anthra-
cycline-only regimen and 4 received a platinum agent-based 
regimen. Following completion of all the cycles of neoadjuvant 
chemotherapy, 46/252 patients receiving combined regimen of 
anthracyclines and taxanes, 14/48 patients in the taxane-only 
subgroup, 1/4 patients receiving platinum agent-based therapy 
and none of the patients (0/19) in the anthracycline-only 
subgroup exhibited pCR (P=0.016). Furthermore, adminis-
tration of neoadjuvant therapy with or without trastuzumab 
was recorded for 329 (98.8%) patients; 71 patients (21.3%) 
received trastuzumab, either concomitant with or sequential 
to chemotherapy, while 258 patients did not receive trastu-
zumab. Following completion of all the cycles of trastuzumab 
treatment, 25/71 patients exhibited pCR (compared to 36/258 
patients with pCR in the no-trastuzumab subgroup, P<0.001). 
The data on neoadjuvant systemic therapy are summarized in 
Table III and Fig. 1.
Discussion
The results of our unadjusted analyses are in line with previ-
ously reported associations between pCR and higher tumor 
grade and the presence or absence of particular biomarkers. In 
our multivariate analysis, HER2 amplification, PR status and 
lack of lymph node involvement were found to be significant 
predictors of pCR.
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Overexpression of HER2, a receptor-like tyrosine kinase, 
is shared by multiple human carcinomas; however, HER2 
amplification in breast cancer is of particular significance 
in determining therapy and predicting outcome. Present in 
20‑30% of all breast cancers, HER2 amplification potentiates 
growth dysregulation, oncogenesis and metastasis, all of which 
contribute to its association with lower disease-free and overall 
survival. Tumors that overexpress HER2 are also more likely 
to be chemoresistant, hence the importance of trastuzumab, 
a HER2-targeting drug, which was first approved by the 
Food and Drug Administration in 1998 in the management 
of these cancers (17). In our study, HER2 overexpression 
was predictive of pCR in the multivariate model containing 
individual biomarkers, thus allowing for ER, PR, and HER2 
Table I. Baseline patient and tumor characteristics.
  pCR, No pCR,
 All patients no. (%) no. (%)
Characteristics (n=333) (n=61) (n=272) P-value
Age, years [median (range)] 48 (20-83) 48 (27-70) 48 (20-83) 0.8
Race    0.9612
  Caucasian 233 (70.0) 43 (70.5) 190 (69.9)
  African American 93 (27.9) 17 (27.9) 76 (27.9)
  Other 7 (2.1) 1 (1.6) 6 (2.2)
Stage    0.0572
  II 234 (70.3) 49 (80.3) 185 (68.0)
  III 99 (29.7) 12 (19.7) 87 (32.0)
Histology    0.0582
  IDC 258 (77.5) 56 (91.8) 202 (74.3)
  ILC 22 (6.6) 1 (1.64) 21 (7.7)
  Mixed IDC and ILC 20 (6.0) 1 (1.64) 19 (7.0)
  Inflammatory 18 (5.4) 1 (1.64) 17 (6.2)
  Other 15 (4.5) 2 (3.28) 13 (4.8)
Grade    0.00065
  1 and 2 119 (35.7) 10 (16.4) 109 (40.1)
  3 211 (63.4) 50 (81.96) 161 (59.2)
  Unknown 3 (0.9) 1 (1.64) 2 (0.7)
Individual biomarkers
  Estrogen    0.026
    ER+ 174 (52.3) 24 (39.3) 150 (55.15)
    ER- 159 (47.7) 37 (60.7) 122 (44.85)
  Progesterone    0.0007
    PR+ 147 (44.1) 15 (24.6) 132 (48.5)
    PR- 186 (55.9) 46 (75.4) 140 (51.5)
  HER2    0.0054
    HER2+ 89 (26.7) 25 (41.0) 64 (23.5)
    HER2- 244 (73.3) 36 (59.0) 208 (76.5)
Composite biomarkers    0.0007
  HR+/HER2+ 54 (16.22) 15 (24.6) 39 (14.3)
  HR-/HER2+ 35 (10.51) 10 (16.4) 25 (9.2)
  HR+/HER2- 130 (39.04) 10 (16.4) 120 (44.1)
  HR-/HER2- 114 (34.23) 26 (42.6) 88 (32.4)
Lymph node involvement    0.0004
  None 117 (35.14) 25 (41.0) 92 (33.82)
  Any 100 (30.03) 6 (9.8) 94 (34.56)
  Unknown  116 (34.6) 30 (49.2) 86 (31.62)
pCR, pathological complete response; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, proges-
terone receptor; HER2, human epidermal growth factor receptor 2.
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statuses to be directly controlled for in relation to one another. 
In the model with composite biomarkers, we also observed 
that the ER+/PR+/HER2- subtype was negatively associated 
with pCR. The aggregate of these findings suggests that there 
may be a complex interplay between the tumor biology and 
treatment with trastuzumab. In reference to pCR rates, we are 
currently unable to disentangle the potential biological effects 
of HER2 amplification from the potential benefits gained from 
trastuzumab treatment. Additional prospective studies are 
required to elucidate this matter.
Lack of lymph node involvement was also found to be a 
significant predictor of pCR in patients with HER2 amplification 
Table III. Neoadjuvant systemic therapy received based.
  pCR No pCR
 All patients no. (%) no. (%)
Characteristics (n=333) (n=61) (n=272) P-value
Trastuzumab therapy    <0.001
  Yes 71 (21.3) 25 (41.0) 46 (16.9)
  No 258 (77.5) 36 (59.0) 222 (81.6)
  Unknown 4 (1.2) 0 (0.0) 4 (1.5)
Chemotherapy grouping    0.0161
  Anthracyclines and taxanes 252 (75.7) 46 (75.4) 206 (75.7)
  Anthracycline-based 19 (5.7) 0 (0.0) 19 (7.0)
  Taxane-based 48 (14.4) 14 (23.0) 34 (12.5)
  Platinum agent-based 4 (1.2) 1 (1.6) 3 (1.1)
  Unknown 10 (3.0) 0 (0.0) 10 (3.7)
pCR, pathological complete response.
Table II. Unadjusted and multivariate logistic regression analyses identifying independent predictors of pCR following neoad-
juvant chemotherapy.
   Multivariate analysis 1  Multivariate analysis 2
 Unadjusted analyses  using composite biomarkersa using individual biomarkers
 ------------------------------------------------------------- ------------------------------------------------------------ -----------------------------------------------------------
Variables OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Ageb 0.997 (0.97-1.02) 0.83 0.99 (0.97-1.02) 0.56 0.99 (0.96-1.02) 0.47
ER- 1.00 (reference)    1.00 (reference)
ER+ 0.53 (0.3-0.93) 0.027 -  1.59 (0.64-3.92) 0.32
PR- 1.00 (reference)    1.00 (reference)
PR+ 0.35 (0.18-0.65) <0.001 -  0.28 (0.11-0.72) 0.0081
HER2- 1.00 (reference)    1.00 (reference)
HER2+ 2.26 (1.26-4.04) 0.0061 -  2.34 (1.23-4.46) 0.0095
Grade 1 and 2 1.00 (reference)  1.00 (reference)  1.00 (reference)
Grade 3 3.39 (1.65-6.96) 0.0035 2.01 (0.86-4.72) 0.48 2.28 (1.0-5.14) 0.14
Stage II 1.00 (reference)  1.00 (reference)  1.00 (reference)
Stage III 0.52 (0.26-1.03) 0.060 0.60 (0.27-1.32) 0.096 0.48 (0.23-1.02) 0.057
No LNI 1.00 (reference)  1.00 (reference)  1.00 (reference)
Any LNI 0.24 (0.092-0.60) 0.0013 0.32 (0.12-0.86) 0.0057 0.28 (0.11-0.79) 0.0039
HR+/HER2+ 1.00 (reference)    1.00 (reference)
HR+/HER2- 0.21 (0.078-0.55) <0.001 0.27 (0.11-0.67) 0.0045 -
HR-/HER2+ 0.96 (0.37-2.47) 0.099 0.95 (0.34-2.65) 0.20 -
HR-/HER2- 0.74 (0.31-1.74) 0.43 0.59 (0.26-1.33) 0.84 -
aThe composite biomarkers assessed in regression model were HR+/HER2+, HR+/HER2-, HR-/HER2+ and HR-̸HER2-. bAnalyzed as a 
continuous variable. pCR, pathological complete response; OR, odds ratio; CI, confidence interval; ER, estrogen receptor; PR, progesterone 
receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; LNI, lymph node involvement.
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without ER or PR expression, even after adjusting for stage 
in the regression model. Lymph node involvement at initial 
presentation is a well-established outcome prognosticator in 
breast cancer and patients with breast pCR but residual nodal 
disease have lower rates of overall survival compared with 
patients who experience breast as well as nodal pCR (1,18).
The assessment of the type of neoadjuvant systemic therapy 
received, highlights the fact that the majority of the treated 
patients at our institution received the standard recommended 
regimen, while also exhibiting improved pCR rates when 
taxanes are used or added to anthracycline therapy. Multiple 
trials evaluating a broad range of chemotherapy drugs have 
also demonstrated that the use of anthracyclines in combina-
tion with taxanes is associated with improved pCR rates (7,10). 
Hence, the consensus statement of the St. Gallen Conference, 
states that a standard neoadjuvant chemotherapy regimen 
should include both an anthracycline and a taxane (19).
Platinum agents are DNA-damaging agents, which have 
been found to be particularly beneficial in improving pCR 
rates in triple-negative breast cancer (TNBC), particularly 
BRCA-mutated tumors (which represent up to 50% of all 
TNBCs). In a meta-analysis of 28 studies, the pooled pCR 
rate noted following addition of a platinum agent to a standard 
neoadjuvant chemotherapy regimen for TNBC was 45% (20). 
Another single-institution study reported pCR rates of 22% 
following neoadjuvant treatment with single-agent cisplatin 
therapy in patients with stage II or III TNBC (21). In our study, 
all 4 patients receiving platinum agents had TNBC and they 
received single-agent therapy with the platinum agent. Of note, 
the sole patient exhibiting pCR following administration of the 
platinum agent had a higher tumor grade (grade 3), lower stage 
(stage II) and no lymph node involvement. To the best of our 
knowledge, a review of the literature has retrieved no data to 
suggest that the improvement in pCR rates following addition 
of platinum agents to standard neoadjuvant chemotherapy 
in TNBC translates to improvements in overall survival or 
disease-free survival. More studies are required to evaluate the 
potential survival benefits of adding platinum‑based therapy to 
standard neoadjuvant chemotherapy for patients with TNBC.
Our study had certain limitations. First, we were unable 
to establish causation, but could only show association, due 
to the fact that retrospective studies are prone to patient and 
treatment selection bias. Additionally, potential confounding 
variables may not always be recognized or recorded, due to 
a lack of knowledge regarding how they interact with the 
outcome of interest. Second, we were unable to control for 
administration of trastuzumab therapy with regard to the asso-
ciation of HER2 amplification with pCR. As the provision of 
HER2-targeted therapy has recently become more standard-
ized, future prospective studies will undoubtedly be better 
equipped to investigate this issue. Third, all the patients in our 
study were treated at a high-volume, NCI-designated compre-
hensive cancer center, although the majority of the patients in 
this country obtain their chemotherapy from non-academic, 
community medical oncologists. This may translate to poten-
tial differences in patient population, treatment received, 
treatment duration, or even the definition of pCR; thus, the 
extent to which our patients exhibit pCR and the reasons why 
they do so, may not reflect the experience of breast cancer 
patients receiving care outside a comprehensive cancer center. 
Finally, details regarding the optimal chemotherapy dose, 
treatment duration, or concurrent vs. sequential administration 
for improving pCR rates were not obtained in this study. Other 
studies are currently underway, however, to address optimal 
administration times in the neoadjuvant setting to improve 
pCR rates.
In conclusion, we found in the regression model using the 
composite HR variable that HR+/HER2‑ tumors were signifi-
cantly less likely to undergo pCR compared with HR+/HER2+ 
tumors, and that tumors with any lymph node involvement were 
significantly less likely to undergo pCR compared with tumors 
without lymph node involvement. Additionally, we found that 
the pCR rates were higher among patients receiving trastu-
zumab or taxane therapy in addition to anthracycline therapy.
Figure 1. Chemotherapeutic regimen used in patients with or without pathological complete response (pCR).
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